A
Alan P. Venook
Researcher at University of California, San Francisco
Publications - 426
Citations - 31367
Alan P. Venook is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 77, co-authored 385 publications receiving 25677 citations. Previous affiliations of Alan P. Venook include Mayo Clinic & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
Al B. Benson,Thomas A. Abrams,Edgar Ben-Josef,P. Mark Bloomston,Jean F. Botha,Bryan M. Clary,Anne M. Covey,Steven A. Curley,Michael I. D'Angelica,Rene Davila,William D. Ensminger,John F. Gibbs,Daniel Laheru,Mokenge P. Malafa,Jorge Marrero,Steven G. Meranze,Sean J. Mulvihill,James O. Park,James A. Posey,Jasgit Sachdev,Riad Salem,Elin R. Sigurdson,Constantinos T. Sofocleous,Jean-Nicolas Vauthey,Alan P. Venook,Laura W. Goff,Yun Yen,Andrew X. Zhu +27 more
Journal ArticleDOI
Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival
Francis Y. Yao,Linda D. Ferrell,Nathan M. Bass,Jessica J. Watson,Peter Bacchetti,Alan P. Venook,Nancy L. Ascher,John P. Roberts +7 more
TL;DR: The current criteria for OLT based on tumor size may be modestly expanded while still preserving excellent survival after OLT, and only pT4 stage and total tumor diameter remained statistically significant in multivariate analysis.
Journal ArticleDOI
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Tim Meyer,Ann-Lii Cheng,Anthony B. El-Khoueiry,Lorenza Rimassa,Baek Yeol Ryoo,Irfan Cicin,Philippe Merle,Yen-Hsun Chen,Joong-Won Park,Jean-Frédéric Blanc,Luigi Bolondi,Heinz Josef Klümpen,Heinz Josef Klümpen,Stephen L. Chan,Vittorina Zagonel,Tiziana Pressiani,Min Hee Ryu,Alan P. Venook,Alan P. Venook,Colin Hessel,Anne E. Borgman-Hagey,Gisela Schwab,Robin Kate Kelley +23 more
TL;DR: Treatment with cabozantinib resulted in longer overall survival and progression‐free survival than placebo among patients with previously treated advanced hepatocellular carcinoma, and the rate of high‐grade adverse events in the cabozaninib group was approximately twice that observed in the placebo group.
Journal ArticleDOI
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson,Alan P. Venook,Lynette Cederquist,Emily Chan,Yi-Jen Chen,Harry S. Cooper,Dustin A. Deming,Paul F. Engstrom,Peter C. Enzinger,Alessandro Fichera,Jean L. Grem,Axel Grothey,Howard S. Hochster,Sarah E. Hoffe,Steven C. Hunt,Ahmed Kamel,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Mary F. Mulcahy,James D. Murphy,Steven J. Nurkin,Leonard B. Saltz,Sunil Sharma,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Christina Wu,Kristina M. Gregory,Deborah A. Freedman-Cass +32 more
TL;DR: This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease and considers treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences.
Journal ArticleDOI
NCCN Clinical Practice Guidelines in Oncology: colon cancer.
Paul F. Engstrom,Juan Pablo Arnoletti,Benson Ab rd,Yi-Jen Chen,Michael A. Choti,Harry S. Cooper,Anne M. Covey,Raza A. Dilawari,Dayna S. Early,Peter C. Enzinger,Marwan Fakih,James W. Fleshman,C. Fuchs,Jean L. Grem,K Kiel,James A. Knol,Lucille Leong,Edward H. Lin,Mary F. Mulcahy,Sujata Rao,David P. Ryan,Leonard B. Saltz,David Shibata,John M. Skibber,Constantinos T. Sofocleous,James P. Thomas,Alan P. Venook,Christopher G. Willett +27 more